To date, I believe I have contributed to shed light on the molecular dynamics involved in the development of EM-AML. Indeed, most of the existing data in literature about this condition are from a clinical perspective, without delving too deeply into the cancer biology. I believe that investigating the role of molecules and signal transduction pathways is essential to add significant building blocks for the development of more personalized therapeutic strategies.